Sciwind Biosciences is a promising player in the Biotechnology and Pharmaceutical industries, with a focus on Health Care. Founded in 2017, the company is committed to pioneering treatments that empower physicians in addressing metabolic disorders, particularly non-alcoholic steatohepatitis (NASH).
Sciwind’s innovation lies in its advanced protein and peptide options designed to offer more effective therapeutics, reinforcing their slogan: "Pioneering treatments to empower physicians in addressing metabolic disorders with advanced protein and peptide options for non-alcoholic steatohepatitis."
The company has successfully garnered substantial support, evidenced by a CNY450.00M investment during a Series C funding round on 11 October 2021. This funding round attracted major investors including IDG Capital, Loyal Valley Capital, LYFE Capital, and Zhengxingu Capital. Sciwind's focus on groundbreaking therapeutics in a niche market positions it as a compelling prospect for continued investment.
